Inclusion Criteria:

- Must be ≥18 years of age

- Phase 1: Must have histologically or cytologically confirmed RAS-mutated (KRAS, NRAS,
or HRAS) solid tumor malignancy that is advanced and unresectable, or metastatic.

- Phase 2a: Must have histologically or cytologically confirmed diagnosis of one of the
following locally advanced unresectable or metastatic solid tumor malignancies:
NRAS-mutant melanoma, KRAS-mutant pancreatic ductal adenocarcinoma (PDAC), KRAS-mutant
non-small cell lung cancer (NSCLC), or KRAS-mutant and APC-wild-type colorectal cancer
(CRC)

- Must have received at least one prior systemic, standard-of-care therapy to treat
their advanced or metastatic disease

- Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1
criteria

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Adequate organ function

Exclusion Criteria:

- Inability to swallow oral medications

- Symptomatic, untreated, or actively progressing known central nervous system (CNS)
metastases

- History or concurrent evidence of retinal vein occlusion (RVO) or current risk factors
for RVO. History of serous retinopathy, retinal edema, or retinal pigment epithelial
detachment (RPED)

- Impaired cardiovascular function or clinically significant cardiac disease

- History of rhabdomyolysis within 3 months prior to start of study treatment

- Active skin disorder requiring systemic treatment within 3 months prior to the start
of study treatment

- Females who are pregnant, breastfeeding, or planning to become pregnant and males who
plan to father a child while enrolled in this study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 7/21/23. Questions regarding updates should be directed to the study team contact.